Insights Center
Thought leadership, news, events — you will find them all here, right at your fingertips. We’ve consolidated the firm’s most popular content in one, easy to search location. Enter a key word or phrase to find pertinent blog posts, articles, press releases, and upcoming events.
Mintz Viewpoints
Showing 7865 - 7872 of 12092 results

Massachusetts Regulatory Overhaul: Hospitals, Clinics, Dialysis Units, and Medical Marijuana – Oh My!
September 15, 2016| Blog| Viewpoint

Robbins: A fighter for Mideast peace, Shimon Peres in battle of his life
September 15, 2016| News

FDA Convenes Two-Day Public Hearing on Human Cell and Tissue Product Regulatory Paradigm
September 15, 2016| Alert| Viewpoint

Ninth Circuit Holds that SOX 304 Clawback Applies to Executives that are Not at Fault
September 14, 2016| Blog| Viewpoint

CMS Proposes Flexible Reporting Under MACRA
September 14, 2016| Blog| Viewpoint

Lawsuit by Algorithm, the Latest Big Data Rage
September 13, 2016| Blog| Viewpoint

Medicaid Managed Care for Brain Injury Waiver Populations
September 13, 2016| Blog| Viewpoint

Immigrant Investor Program Changes Pushed in Congress as Deadline Looms
September 13, 2016| News
News & Press Releases
Mintz advised the creators of Morbid, one of the top-charting true crime podcasts, in a multi-year agreement to move to SiriusXM from Wondery. The deal gives SiriusXM exclusive advertising rights for the audio and video formats of the podcast.
Mintz Advises CVC DIF in Acquisition of SBA Communications’ Canadian Tower Infrastructure Platform
August 06, 2025
Mintz advised CVC DIF, the dedicated infrastructure investment strategy of global private markets manager CVC, in its agreement to acquire SBA Communications’ Canadian wireless tower business, one of Canada’s leading independent owners and operators of wireless communications towers. The transaction is expected to close in the fourth quarter of 2025, subject to customary closing conditions.
Mintz advised the underwriters in connection with a $69 million public offering by Larimar Therapeutics, Inc. of 21,562,500 shares of its common stock at a price to the public of $3.20 per share. The gross proceeds to Larimar from the offering were $69 million before deducting underwriting discounts and commissions and other offering expenses.
Events
Podcasts

Mintz On Air: Practical Policies — A Private Equity Non-Compete Primer
July 15, 2025| Podcast|

Health Law Diagnosed – Best Practices for Communicating with the FDA
July 9, 2025| Podcast|
